Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) is engaged as an artificial intelligence-driven precision cardiovascular medicine company, which is focused on developing products and treatments for cardiovascular disease (CVD) prevention and early detection. Shares of the CVD diagnostics company are skyrocketing 146% through early trading on Tuesday, February 28, 2023. Over the past three months, Cardio Diagnostics has seen average daily volume of 512,790 shares. However, volume of 55.35 million shares or dollar volume of around $171.03 million, has already exchanged hands through early trading.
Shares of Cardio Diagnostics are soaring after the company announced the launch of PrecisionCHD, an integrated epigenetic-genetic blood test that can detect early stages of coronary heart disease (CHD). PrecisionCHD represents the second clinical test that has been developed using the company proprietary AI-focused Integrated Epigenetic-Genetic Engine. The initial test product, Epi+Gen CHD, is a three-year CHD risk assessment test, which was launched in 2021.
The PrecisionCHD product uses epigenetic and genetic biomarkers along-side a machine-learning model developed using billions of genomic and epigenomic data points. As a result, the PrecisionCHD test is able to detect CHD with sensitivity greater than 75% for both men and women. The key to the strong sensitivity in the test is derived from a provider-only Actionable Clinical Intelligence platform, which maps out a patient’s unique biomarker profile and factors in modifiable risk factors like diabetes, hypertension and other factors that can increase the risk for CHD.
“While we are incredibly proud of the work we’ve done to bring PrecisionCHD to the market and the impact this test can have in improving the lives of millions around the world, we understand how timely it was that we were building in an era of Artificial Intelligence, high-performance computing, and high-throughput epigenetics,” said Meesha Dogan, Ph.D., the CEO and Co-Founder of Cardio Diagnostics. “PrecisionCHD would not have been possible without Cardio Diagnostics being at the forefront of pioneering technology at the intersection of epigenetics, genetics, and Artificial Intelligence focused on reducing the burden of the number one killer. PrecisionCHD and Epi+Gen CHD are tools to get ahead of coronary heart disease for healthcare providers, employers, and payers in this era because this is the age of AI-enabled precision medicine.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
